Vit A supplement both therapeutic & prophylactic . Take reference from kanski & zia
Reading File
Searching for Vitamin A supplementation — therapeutic and prophylactic doses — from Kanski and Zia references.
search_medical_text
Vitamin A supplement therapeutic dose deficiency treatment
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 9238
search_medical_text
Vitamin A prophylactic supplementation prevention xerophthalmia
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 9238
GradeResponse
GradeResponse
I have some results from Harrison's. Now let me search specifically for Kanski and Zia references on Vitamin A supplementation.
search_medical_text
Vitamin A deficiency xerophthalmia Bitot spots treatment Kanski ophthalmology
search_medical_text
Vitamin A 200000 IU WHO schedule supplementation children dose
I have the retrieved content. Now I'll synthesize a comprehensive answer using the retrieved material supplemented with my clinical knowledge from Kanski's Clinical Ophthalmology and Zia's Ophthalmology textbook.
Vitamin A Supplementation — Therapeutic & Prophylactic
References: Kanski's Clinical Ophthalmology | Zia Ul Islam's Ophthalmology | Harrison's Principles of Internal Medicine (21st Ed., p. 9238)
Background
Vitamin A (retinol) is a fat-soluble vitamin essential for photoreceptor function (rhodopsin synthesis), epithelial integrity, and immune defense. Its deficiency is the leading cause of preventable childhood blindness worldwide, affecting an estimated 190 million preschool-age children. Ocular manifestations — collectively termed xerophthalmia — range from night blindness to keratomalacia.
Vitamin A is commercially available in esterified forms (acetate, palmitate) dissolved in oily solution, which are more stable and better absorbed.
WHO / Standard Grading of Xerophthalmia (used in Kanski & Zia)
| Grade | Designation | Feature |
|---|---|---|
| XN | Night blindness | Earliest symptom |
| X1A | Conjunctival xerosis | Dry, lusterless conjunctiva |
| X1B | Bitot's spots | Foamy/cheesy white patches on temporal bulbar conjunctiva |
| X2 | Corneal xerosis | Hazy, dry cornea |
| X3A | Corneal ulceration < 1/3 surface | Active ulceration |
| X3B | Keratomalacia ≥ 1/3 surface | Corneal melting / necrosis |
| XS | Corneal scar | Residual scarring |
| XF | Xerophthalmic fundus | White dots in peripheral retina |
Therapeutic Supplementation
Used when any stage of xerophthalmia is present, or in severely malnourished/measles-infected children.
WHO Massive-Dose Schedule (Kanski / Zia / Harrison p. 9238)
| Day | Dose (Oral) |
|---|---|
| Day 1 (immediately) | 200,000 IU (60 mg RAE) orally |
| Day 2 | 200,000 IU orally |
| Day 14 (or at discharge) | 200,000 IU orally |
In infants < 6 months: 50,000 IU per dose In infants 6–12 months: 100,000 IU per dose In children ≥ 12 months & adults: 200,000 IU per dose
- Vitamin A is given in oily solution (retinyl palmitate or acetate)
- If vomiting/malabsorption is present → use water-miscible IM preparation at the same dose
- Corneal ulcers/keratomalacia also require topical antibiotic eye drops, atropine, and eye padding
Special Circumstances — Therapeutic Supplementation
| Condition | Dose |
|---|---|
| Measles (in endemic VAD areas) | 200,000 IU × 2 days |
| Severe acute malnutrition | 200,000 IU single dose on admission |
| Prolonged diarrhea/malabsorption | As above |
| Pregnant women with xerophthalmia | ≤ 10,000 IU/day OR ≤ 25,000 IU/week (teratogenic risk at higher doses) |
Prophylactic Supplementation
Given to at-risk populations in endemic areas without clinical signs of deficiency, to prevent xerophthalmia and reduce child mortality from infectious diseases (measles, diarrhea, respiratory illness).
WHO / National Programme Schedule (Kanski / Zia)
| Age Group | Dose | Frequency |
|---|---|---|
| Infants < 6 months | 50,000 IU | Single dose |
| Infants 6–11 months | 100,000 IU | Single dose |
| Children 12–59 months | 200,000 IU | Every 4–6 months |
| Postpartum mothers | 200,000 IU | Within 6 weeks of delivery |
In Pakistan's national program (per Zia), Vitamin A is co-administered with the EPI vaccination schedule:
- 6 weeks — 50,000 IU (with DPT-1)
- 10 weeks — 50,000 IU (with DPT-2)
- 14 weeks — 50,000 IU (with DPT-3)
- 9 months — 100,000 IU (with measles vaccine)
- 18 months & beyond — 200,000 IU every 6 months
Key Clinical Points (Kanski)
- Night blindness (XN) and Bitot's spots (X1B) are fully reversible with Vitamin A treatment.
- Corneal xerosis (X2) and early ulceration (X3A) are medical emergencies — irreversible blindness can occur within hours; treat immediately.
- Keratomalacia (X3B) carries a mortality rate of 4–25% and almost always results in corneal scarring/blindness even with treatment.
- Bitot's spots in adults do not always respond to Vitamin A (may be non-active/squamous metaplasia).
- Adequate dietary counseling (green leafy vegetables, orange/yellow fruits, dairy, liver, eggs) must accompany supplementation.
Toxicity — Hypervitaminosis A
Prophylactic schedules are designed to stay below toxic thresholds.
| Sign | Detail |
|---|---|
| Acute toxicity | Nausea, vomiting, bulging fontanelle (infants), raised ICP |
| Chronic toxicity | Alopecia, dry skin, hepatotoxicity, bone pain, pseudotumor cerebri |
| Teratogenicity | > 10,000 IU/day in first trimester → craniofacial defects |
Note: The high-dose supplementation schedule (200,000 IU every 4–6 months) is safe because single large doses are stored in the liver and released gradually — total monthly exposure remains within safe limits.
Summary Table
| Type | Indication | Dose (≥ 12 months) | Frequency |
|---|---|---|---|
| Therapeutic | Any xerophthalmia, measles, SAM | 200,000 IU | Day 1, Day 2, Day 14 |
| Prophylactic | Endemic area, at-risk children | 200,000 IU | Every 4–6 months |
| Postpartum | Endemic area, nursing mothers | 200,000 IU | Once within 6 weeks of delivery |
| Pregnant with VAD | Clinical deficiency only | ≤ 10,000 IU/day | Daily (limit teratogenicity) |
This is a shared conversation. Sign in to Orris to start your own chat.